Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00024115 | BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 28, 2015 | clinicaltrials |
| NCT00903942 | Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | University of RochesterOTHER | 1 | Apr 27, 2015 | clinicaltrials |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Apr 24, 2015 | clinicaltrials |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | withdrawn | Phase 2 | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | withdrawn | Phase 3 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT01317212 | Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme | withdrawn | Phase 1 | 0 | North Bristol NHS TrustOTHER | 1 | Apr 17, 2015 | clinicaltrials |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | withdrawn | Phase 2 | 0 | Meir Medical CenterOTHER | 0 | Apr 16, 2015 | clinicaltrials |
| NCT01801163 | A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 | 0 | Indiana UniversityOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT01671215 | Endometrial and Myometrial Changes, With and Without Fibroids | withdrawn | — | 0 | Meir Medical CenterOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01851408 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 15, 2015 | clinicaltrials |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. | withdrawn | Phase 4 | 0 | NovartisINDUSTRY | 0 | Apr 14, 2015 | clinicaltrials |
| NCT00969917 | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma | withdrawn | Phase 2 | 0 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 14, 2015 | clinicaltrials |
| NCT01065545 | The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Apr 10, 2015 | clinicaltrials |
| NCT00549835 | Acupuncture for Mucositis Pain in Cancer Care | withdrawn | N/A | 0 | Johns Hopkins UniversityOTHER | 1 | Apr 8, 2015 | clinicaltrials |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | withdrawn | Phase 2 | 0 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Apr 6, 2015 | clinicaltrials |
| NCT02310971 | Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas | withdrawn | Phase 2 | 0 | Prima BioMed LtdINDUSTRY | 0 | Apr 3, 2015 | clinicaltrials |
| NCT01732432 | Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)(EAOC) | withdrawn | — | 0 | University Hospital, Basel, SwitzerlandOTHER | 0 | Apr 1, 2015 | clinicaltrials |
| NCT00210340 | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis | withdrawn | Phase 1 | 0 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 0 | Mar 30, 2015 | clinicaltrials |
| NCT01953952 | Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 1 | Mar 20, 2015 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT00659399 | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression | withdrawn | Phase 1 | 0 | NYU Langone HealthOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT00661336 | A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT01225510 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Mar 11, 2015 | clinicaltrials |
| NCT01133262 | Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device | withdrawn | — | 0 | Washington University School of MedicineOTHER | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00002790 | Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00723658 | S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00833534 | Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00845104 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00939328 | S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Mar 6, 2015 | clinicaltrials |
| NCT01055301 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01048983 | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 5, 2015 | clinicaltrials |
| NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02034968 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02041819 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma(DMV) | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT00803842 | Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash | withdrawn | N/A | 0 | Northwestern UniversityOTHER | 0 | Feb 26, 2015 | clinicaltrials |
| NCT02011594 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT01353794 | Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer(POWER-NEXT) | withdrawn | — | 0 | BayerINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT01386398 | Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 21, 2015 | clinicaltrials |
| NCT02297425 | A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Jan 12, 2015 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT01593579 | Autonomic Phenotype Before and After Akt Inhibition | withdrawn | — | 0 | Vanderbilt UniversityOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01927393 | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02207764 | Reiki as a Complementary Therapy: A Pilot Study | withdrawn | N/A | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Syed JafriOTHER | 1 | Dec 18, 2014 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2015source: clinicaltrials